The present disclosure provides albumin-binding radioactive metal complexes and uses thereof, including diagnosing and treating disease.

Despite the widespread use of nanotechnology in radio-imaging applications, lipoprotein based delivery systems received only limited attention so far. The subject application provides for the synthesis of a novel hydrophobic radio-imaging tracer. This tracer, comprising a hydrazinonicotinic acid (HYNIC)-N-dodecylamide and .sup.99mTc conjugate can be encapsulated into rHDL nanoparticles (NPs). These rHDL NPs can selectively target the Scavenger Receptor type B1 (SR-B1) that is overexpressed on most cancer cells due to excess demand for cholesterol for membrane biogenesis and thus can target tumors in-vivo. Details of the tracer synthesis, characterization of rHDL/tracer complex, in-vitro uptake, stability studies and in-vivo application of this new radio-imaging approach are provided.

The present invention relates to a labeling procedure for the incorporation, in mild reaction conditions, of sensitive and thermosensitive targeting molecules into a [99m Tc(N)(PNP)]-based compound suitable for a kit formulation.

The present invention relates to cell radiolabelling agents. The invention provides a method of preparing oxine-containing cell radiolabelling agents, a kit for the preparation of oxine-containing cell radiolabelling agents and a formulation for the preparation of oxine-containing cell radiolabelling agents, in particular .sup.89Zr-oxine cell radiolabelling agents.

Disclosed is a polymetalloxane including a constituent unit represented by the following general formula (1), which stably exists in a transparent and uniform state in a solution and can form a homogeneous cured film: ##STR00001##
wherein R.sup.1 is an organic group and at least one of R.sup.1 is an (R.sup.3.sub.3SiO—) group, R.sup.3 is optionally selected from specific groups, R.sup.2 is optionally selected from specific groups, when plural R.sup.1, R.sup.2, and R.sup.3 exist, they may be the same or different, M represents a specific metal atom, m is an integer indicating a valence of a metal atom M, and a is an integer of 1 to (m−2).

Imaging and radiotherapeutics agents targeting fibroblast-activation protein-α (FAP-α) and their use in imaging and treating FAP-α related diseases and disorders are disclosed.

This invention relates to radioactive, bone-seeking, pharmaceutical compositions that are administered multiple times to a patient, have a lower impurity profile, a longer shelf life, and are less expensive to prepare.

The disclosure relates to compositions comprising (i) at least one fluorocarbon, (ii) at least one fluorous hydroxamic acid chelator, and in some instances, (iii) at least one radioisotope. The disclosure also relates to methods for using such compositions, methods of making such compositions, and kits for making such compositions.

A method for preparing a complex comprising a radioisotope of gallium for use in radiotherapy or in a medical imaging procedure, said method comprising adding a gallium radioisotope solution obtained directly from a gallium radionuclide generator to a composition comprising a pharmaceutically acceptable buffer and optionally also a pharmaceutically acceptable basic reagent, in amounts sufficient to increase the pH to a level in the range of 3 to 8, wherein the composition further comprises a chelator that is able to chelate radioactive gallium within said pH range and at moderate temperature, said chelator being optionally linked to a biological targeting agent. Kits and compositions for use in the method are also described and claimed.

The present invention relates to a radiopharmaceutical compound or composition for Positron Emission Tomography (PET) imaging of interleukin-2 (IL2) receptor positive cells, in particular, .sup.68Ga-radiolabelled interleukin-2 such as a desalanyl-1, serine-125 human interleukin-2 (dsIL2) radiolabelled with a short-lived PET radioisotope (or radionuclide) gallium-68 (.sup.68Ga) by using tris-(hydroxypyridinone-maleimide) (THP-mal) as a chelator. The invention concerns also a kit comprising dsIL2 linked to THP-mal which can be added with .sup.68Ga in order to obtain the above mentioned radiopharmaceutical, at room temperature, suitable for PET imaging, a process for the preparation of the radiopharmaceutical and its use in medical and diagnostic field.